By Marleen Kaesebier and Patricia Weiss ZURICH, April 22 (Reuters) - Swiss drugmaker Roche on Wednesday said it was ...

Mapi Pharma’s GA Depot was associated with stable disability scores over time in people with both RMS and PPMS, data show.

Late-breaking Phase III FENhance 1 and 2 study results showed superiority of investigational fenebrutinib compared to teriflunomide in reducing relapses and brain lesions in relapsing multiple ...

The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of Roche's top-selling drug ocrelizumab (Ocrevus) for treating primary progressive multiple sclerosis (PPMS)—a ...

Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depot injectable treatments, will present efficacy data ...

Roche has shared details of fatalities in its phase 3 relapsing multiple sclerosis (RMS) trials, revealing that deaths from ...

– Reduced Relative Risk of 24-Week Confirmed Disability Worsening Events by 20% in Overall Study Population Compared to Placebo; Even More Prominent 30% Reduction in High Unmet Need Population of ...

PERSEUS phase 3 study in primary progressive multiple sclerosis did not meet its primary endpoint in delaying time to onset of 6-month composite confirmed disability progression compared to placebo ...

SAN DIEGO -- Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple sclerosis (SPMS), the phase III HERCULES trial showed. The Bruton's ...

The US Food and Drug Administration (FDA) is reviewing a petition to revoke the approval of ocrelizumab for the treatment of ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today new data from the positive Phase III FENhance 1 and 2 studies, which met their primary endpoint. The studies showed ...